Gyre Therapeutics presents integrated pipeline for fibrosis, inflammatory diseases and cancer
Gyre Therapeutics filed an 8-K with a presentation outlining its fully-integrated biopharmaceutical platform combining operations with Cullgen Inc., featuring multiple product candidates across fibrosis, inflammatory and oncology indications. The filing details clinical developme
View filing at SEC.gov →